Treatment for down syndrome-related accelerated aging
AssigneesThe Texas A&M University System, The Trustees of Indiana University
InventorsThomas A Kent, Paul J. Derry, Kenneth R. Olson
Life of this patent
Estimating the term…
Abstract
A method of treating a Down syndrome (DS) subject with functional or at risk of decline of organ systems associated with accelerated aging due to over-production of H2S is disclosed. That method contemplates administering a pharmaceutical composition containing a H2S-reducing effective amount of hydrophilic polymer-substituted oxidized carbon nanoparticles (OCNPs) and an optional potentiating amount of lipoic acid or dihydrolipoic acid dissolved or dispersed in a physiologically acceptable diluent to the subject. The pharmaceutical composition can be administered parenterally as a liquid or per os as a solid or liquid.
Claims24
A method for treating a Down syndrome (DS) subject presenting with functional decline of organ systems associated with accelerated aging due to over-production of H2S that comprises administering a pharmaceutical composition containing a H2S-reducing effective amount of hydrophilic polymer-substituted oxidized carbon nanoparticles (OCNPs) dissolved or dispersed in a physiologically acceptable diluent to the subject.
A method for treating a Down syndrome (DS) subject presenting with functional decline of organ systems associated with accelerated aging due to over-production of H2S that comprises
- administering a pharmaceutical composition containing a concentration of about 0.1 to about 10 mg/kg of poly(ethylene glycol)-substituted oxidized carbon nanoparticles (PEG-OCNPs) dissolved or dispersed in a physiologically acceptable diluent to the subject,
- wherein said PEG substituent has average molecular weight of about 2000 to about 10,000 Da, and said PEG-OCNPs contain an average of about 3 to about 12 PEG substituents per particle.
Dependencies are inferred from the claim text.